Tianyuan Xu

1.8k total citations
51 papers, 1.1k citations indexed

About

Tianyuan Xu is a scholar working on Surgery, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tianyuan Xu has authored 51 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Surgery, 14 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tianyuan Xu's work include Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (12 papers) and Urological Disorders and Treatments (6 papers). Tianyuan Xu is often cited by papers focused on Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (12 papers) and Urological Disorders and Treatments (6 papers). Tianyuan Xu collaborates with scholars based in China, Nepal and United States. Tianyuan Xu's co-authors include Zhoujun Shen, Xianjin Wang, Leilei Xia, Shan Zhong, Zhaowei Zhu, Shan Zhong, Xiaohua Zhang, Minguang Zhang, Shanwen Chen and Yifan Shen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Advanced Functional Materials.

In The Last Decade

Tianyuan Xu

49 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tianyuan Xu China 22 513 360 342 208 152 51 1.1k
Xiaobing Ju China 21 208 0.4× 494 1.4× 720 2.1× 418 2.0× 126 0.8× 75 1.3k
Enrique Gómez‐Gómez Spain 17 193 0.4× 293 0.8× 381 1.1× 200 1.0× 92 0.6× 77 829
Raffaella Santi Italy 18 328 0.6× 359 1.0× 201 0.6× 194 0.9× 245 1.6× 94 1.3k
Xiaoxin Meng China 18 133 0.3× 390 1.1× 570 1.7× 314 1.5× 94 0.6× 44 944
Tsuyoshi Nakayama Japan 17 155 0.3× 275 0.8× 307 0.9× 83 0.4× 116 0.8× 55 813
Roman Metzger Germany 18 316 0.6× 130 0.4× 252 0.7× 44 0.2× 68 0.4× 58 870
Maurizio Buscarini Italy 19 427 0.8× 232 0.6× 289 0.8× 37 0.2× 159 1.0× 73 1.0k
M.J. Requena Spain 18 567 1.1× 179 0.5× 274 0.8× 88 0.4× 261 1.7× 48 1.1k
Enver Vardar Türkiye 14 430 0.8× 151 0.4× 188 0.5× 166 0.8× 242 1.6× 68 1.2k

Countries citing papers authored by Tianyuan Xu

Since Specialization
Citations

This map shows the geographic impact of Tianyuan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tianyuan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tianyuan Xu more than expected).

Fields of papers citing papers by Tianyuan Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tianyuan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tianyuan Xu. The network helps show where Tianyuan Xu may publish in the future.

Co-authorship network of co-authors of Tianyuan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Tianyuan Xu. A scholar is included among the top collaborators of Tianyuan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tianyuan Xu. Tianyuan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zheng, Zhong, Rui Sun, Xiangqin Weng, et al.. (2025). Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma. Signal Transduction and Targeted Therapy. 10(1). 29–29. 3 indexed citations
2.
Zhang, Jingcheng, Wentao Zhang, Liu Ji, et al.. (2024). SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis. Molecular Biomedicine. 5(1). 36–36. 2 indexed citations
3.
Wang, Keyi, Weipu Mao, Xinran Song, et al.. (2024). Composition‐Reinforced Polydopamine Nanoenzyme for Improved Impairment of Prostatitis‐Damaged Sexual Behavior and Enhanced Anti‐Prostate Cancer. Advanced Functional Materials. 34(19). 9 indexed citations
4.
Song, Wei, Heng Zhang, Yi Lü, et al.. (2024). KHSRP knockdown inhibits papillary renal cell carcinoma progression and sensitizes to gemcitabine. Frontiers in Pharmacology. 15. 1446920–1446920. 1 indexed citations
5.
Xu, Tianyuan, Zhong Zheng, & Weili Zhao. (2023). Advances in the multi-omics landscape of follicular lymphoma. International Journal of Biological Sciences. 19(6). 1955–1967. 5 indexed citations
6.
Zheng, Zongtai, et al.. (2021). Integrating multiparametric MRI radiomics features and the Vesical Imaging-Reporting and Data System (VI-RADS) for bladder cancer grading. Abdominal Radiology. 46(9). 4311–4323. 23 indexed citations
7.
Fu, Zhichao, Jianfei Wang, Yadong Yang, et al.. (2021). RNA-seq analysis of non-muscular invasive bladder cancer to reveal different gene expression profiles between smoking and non-smoking patients.. Journal of Clinical Oncology. 39(6_suppl). 478–478.
8.
9.
Zheng, Zongtai, et al.. (2021). Magnetic resonance imaging-based radiomics signature for preoperative prediction of Ki67 expression in bladder cancer. Cancer Imaging. 21(1). 65–65. 20 indexed citations
10.
Dong, Fan, Yifan Shen, Tianyuan Xu, et al.. (2018). Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis. World Journal of Surgical Oncology. 16(1). 61–61. 12 indexed citations
11.
Dong, Fan, Tianyuan Xu, Yifan Shen, et al.. (2018). Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: a population-based, propensity score-matched study. International Journal of Clinical Oncology. 24(3). 296–305. 21 indexed citations
12.
Dong, Fan, Yifan Shen, Fengbin Gao, et al.. (2018). Nomograms to Predict Individual Prognosis of Patients with Primary Small Cell Carcinoma of the Bladder. Journal of Cancer. 9(7). 1152–1164. 46 indexed citations
13.
Gao, Fengbin, Xiao‐Jing Wang, Shanwen Chen, et al.. (2018). CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells. Oncology Reports. 40(5). 2445–2454. 13 indexed citations
14.
Wang, Xiaojing, et al.. (2017). Targeting of CCN2 suppresses tumor progression and improves chemo-sensitivity in urothelial bladder cancer. Oncotarget. 8(39). 66316–66327. 7 indexed citations
15.
Chen, Fang, Xin Xie, Tianyuan Xu, et al.. (2017). Segmental ureterectomy is not inferior to radical nephroureterectomy for either middle or distal ureter urothelial cell carcinomas within 3.5 cm. International Urology and Nephrology. 49(7). 1177–1182. 7 indexed citations
16.
Xia, Leilei, Xianjin Wang, Tianyuan Xu, et al.. (2015). Robotic versus Open Radical Cystectomy: An Updated Systematic Review and Meta-Analysis. PLoS ONE. 10(3). e0121032–e0121032. 56 indexed citations
17.
Xu, Tianyuan, Xianjin Wang, Leilei Xia, et al.. (2014). Robot-Assisted Prostatectomy in Obese Patients: How Influential Is Obesity on Operative Outcomes?. Journal of Endourology. 29(2). 198–208. 25 indexed citations
18.
Zhang, Xiao‐Hua, Xianjin Wang, Liang Qin, et al.. (2014). The Dual mTORC1 and mTORC2 Inhibitor PP242 Shows Strong Antitumor Activity in a Pheochromocytoma PC12 Cell Tumor Model. Urology. 85(1). 273.e1–273.e7. 10 indexed citations
19.
Xu, Tianyuan, Zhaowei Zhu, Xianjin Wang, et al.. (2013). Predicting Recurrence and Progression in Chinese Patients With Nonmuscle-invasive Bladder Cancer Using EORTC and CUETO Scoring Models. Urology. 82(2). 387–393. 26 indexed citations
20.
Zhang, Xiaohua, Zhaowei Zhu, Tianyuan Xu, & Zhoujun Shen. (2013). Factors Affecting Complete Hypertension Cure after Adrenalectomy for Aldosterone-Producing Adenoma: Outcomes in a Large Series. Urologia Internationalis. 90(4). 430–434. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaobing Ju Breakdown of academic impact, for papers by Enrique Gómez‐Gómez Breakdown of academic impact, for papers by Raffaella Santi Breakdown of academic impact, for papers by Xiaoxin Meng Breakdown of academic impact, for papers by Tsuyoshi Nakayama Breakdown of academic impact, for papers by Roman Metzger Breakdown of academic impact, for papers by Maurizio Buscarini Breakdown of academic impact, for papers by M.J. Requena Breakdown of academic impact, for papers by Enver Vardar
Rankless by CCL
2026